Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Page: 102

Published Date: 08 Jan 2022

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The Chemotherapy-Induced Nausea and Vomiting (CINV) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Chemotherapy-Induced Nausea and Vomiting (CINV) market size is estimated to be worth US$  million in 2021 and is forecast to a readjusted size of USD  million by 2028 with a CAGR of  % during review period. Hospitals accounting for  % of the Chemotherapy-Induced Nausea and Vomiting (CINV) global market in 2021, is projected to value USD  million by 2028, growing at a  % CAGR in next six years. While CINV segment is altered to a  % CAGR between 2022 and 2028.

Global key companies of Chemotherapy-Induced Nausea and Vomiting (CINV) include Merck, Eisai, ProStrakan, Helsinn Holding, and Mundipharma, etc. In terms of revenue, the global top four players hold a share over  % in 2021.

Market segmentation
Chemotherapy-Induced Nausea and Vomiting (CINV) market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
    CINV
    PONV

Market segment by Application, can be divided into
    Hospitals
    Ambulatory Surgical Centers
    Diagnostic Centers

Market segment by players, this report covers
    Merck
    Eisai
    ProStrakan
    Helsinn Holding
    Mundipharma
    Qilu Pharma
    Teva
    Novartis
    Heron Therapeutics
    Roche
    Mylan
    Tesaro

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
    South America (Brazil, Argentina, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Chemotherapy-Induced Nausea and Vomiting (CINV) product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Chemotherapy-Induced Nausea and Vomiting (CINV), with revenue, gross margin and global market share of Chemotherapy-Induced Nausea and Vomiting (CINV) from 2019 to 2022.
Chapter 3, the Chemotherapy-Induced Nausea and Vomiting (CINV) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Chemotherapy-Induced Nausea and Vomiting (CINV) market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Chemotherapy-Induced Nausea and Vomiting (CINV) research findings and conclusion, appendix and data source.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Chemotherapy-Induced Nausea and Vomiting (CINV)
    1.2 Classification of Chemotherapy-Induced Nausea and Vomiting (CINV) by Type
        1.2.1 Overview: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type: 2017 Versus 2021 Versus 2028
        1.2.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Type in 2021
        1.2.3 CINV
        1.2.4 PONV
    1.3 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market by Application
        1.3.1 Overview: Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application: 2017 Versus 2021 Versus 2028
        1.3.2 Hospitals
        1.3.3 Ambulatory Surgical Centers
        1.3.4 Diagnostic Centers
    1.4 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size & Forecast
    1.5 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast by Region
        1.5.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Region: 2017 VS 2021 VS 2028
        1.5.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Region, (2017-2022)
        1.5.3 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Prospect (2017-2028)
        1.5.4 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Prospect (2017-2028)
        1.5.5 Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Prospect (2017-2028)
        1.5.6 South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Prospect (2017-2028)
        1.5.7 Middle East and Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Prospect (2017-2028)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Drivers
        1.6.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Restraints
        1.6.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Trends Analysis

2 Company Profiles
    2.1 Merck
        2.1.1 Merck Details
        2.1.2 Merck Major Business
        2.1.3 Merck Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
        2.1.4 Merck Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.1.5 Merck Recent Developments and Future Plans
    2.2 Eisai
        2.2.1 Eisai Details
        2.2.2 Eisai Major Business
        2.2.3 Eisai Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
        2.2.4 Eisai Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.2.5 Eisai Recent Developments and Future Plans
    2.3 ProStrakan
        2.3.1 ProStrakan Details
        2.3.2 ProStrakan Major Business
        2.3.3 ProStrakan Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
        2.3.4 ProStrakan Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.3.5 ProStrakan Recent Developments and Future Plans
    2.4 Helsinn Holding
        2.4.1 Helsinn Holding Details
        2.4.2 Helsinn Holding Major Business
        2.4.3 Helsinn Holding Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
        2.4.4 Helsinn Holding Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.4.5 Helsinn Holding Recent Developments and Future Plans
    2.5 Mundipharma
        2.5.1 Mundipharma Details
        2.5.2 Mundipharma Major Business
        2.5.3 Mundipharma Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
        2.5.4 Mundipharma Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.5.5 Mundipharma Recent Developments and Future Plans
    2.6 Qilu Pharma
        2.6.1 Qilu Pharma Details
        2.6.2 Qilu Pharma Major Business
        2.6.3 Qilu Pharma Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
        2.6.4 Qilu Pharma Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.6.5 Qilu Pharma Recent Developments and Future Plans
    2.7 Teva
        2.7.1 Teva Details
        2.7.2 Teva Major Business
        2.7.3 Teva Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
        2.7.4 Teva Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.7.5 Teva Recent Developments and Future Plans
    2.8 Novartis
        2.8.1 Novartis Details
        2.8.2 Novartis Major Business
        2.8.3 Novartis Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
        2.8.4 Novartis Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.8.5 Novartis Recent Developments and Future Plans
    2.9 Heron Therapeutics
        2.9.1 Heron Therapeutics Details
        2.9.2 Heron Therapeutics Major Business
        2.9.3 Heron Therapeutics Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
        2.9.4 Heron Therapeutics Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.9.5 Heron Therapeutics Recent Developments and Future Plans
    2.10 Roche
        2.10.1 Roche Details
        2.10.2 Roche Major Business
        2.10.3 Roche Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
        2.10.4 Roche Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.10.5 Roche Recent Developments and Future Plans
    2.11 Mylan
        2.11.1 Mylan Details
        2.11.2 Mylan Major Business
        2.11.3 Mylan Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
        2.11.4 Mylan Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.11.5 Mylan Recent Developments and Future Plans
    2.12 Tesaro
        2.12.1 Tesaro Details
        2.12.2 Tesaro Major Business
        2.12.3 Tesaro Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
        2.12.4 Tesaro Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.12.5 Tesaro Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Share by Players (2019, 2020, 2021, and 2022)
    3.2 Market Concentration Rate
        3.2.1 Top 3 Chemotherapy-Induced Nausea and Vomiting (CINV) Players Market Share in 2021
        3.2.2 Top 10 Chemotherapy-Induced Nausea and Vomiting (CINV) Players Market Share in 2021
        3.2.3 Market Competition Trend
    3.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Players Head Office, Products and Services Provided
    3.4 Chemotherapy-Induced Nausea and Vomiting (CINV) Mergers & Acquisitions
    3.5 Chemotherapy-Induced Nausea and Vomiting (CINV) New Entrants and Expansion Plans

4 Market Size Segment by Type
    4.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Market Share by Type (2017-2022)
    4.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Forecast by Type (2023-2028)

5 Market Size Segment by Application
    5.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Application (2017-2022)
    5.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application
    6.1 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2017-2028)
    6.2 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2028)
    6.3 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country
        6.3.1 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2017-2028)
        6.3.2 United States Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
        6.3.3 Canada Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
        6.3.4 Mexico Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application
    7.1 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2017-2028)
    7.2 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2028)
    7.3 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country
        7.3.1 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2017-2028)
        7.3.2 Germany Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
        7.3.3 France Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
        7.3.4 United Kingdom Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
        7.3.5 Russia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
        7.3.6 Italy Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2017-2028)
    8.2 Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2028)
    8.3 Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Region
        8.3.1 Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Region (2017-2028)
        8.3.2 China Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
        8.3.3 Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
        8.3.4 South Korea Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
        8.3.5 India Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
        8.3.6 Southeast Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
        8.3.7 Australia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application
    9.1 South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2017-2028)
    9.2 South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2028)
    9.3 South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country
        9.3.1 South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2017-2028)
        9.3.2 Brazil Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
        9.3.3 Argentina Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2017-2028)
    10.2 Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2028)
    10.3 Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country
        10.3.1 Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2017-2028)
        10.3.2 Turkey Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
        10.3.3 Saudi Arabia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)
        10.3.4 UAE Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
    Table 2. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
    Table 3. Global Market Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
    Table 4. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million) by Region (2017-2022)
    Table 5. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Region (2023-2028)
    Table 6. Merck Corporate Information, Head Office, and Major Competitors
    Table 7. Merck Major Business
    Table 8. Merck Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
    Table 9. Merck Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 10. Eisai Corporate Information, Head Office, and Major Competitors
    Table 11. Eisai Major Business
    Table 12. Eisai Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
    Table 13. Eisai Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 14. ProStrakan Corporate Information, Head Office, and Major Competitors
    Table 15. ProStrakan Major Business
    Table 16. ProStrakan Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
    Table 17. ProStrakan Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 18. Helsinn Holding Corporate Information, Head Office, and Major Competitors
    Table 19. Helsinn Holding Major Business
    Table 20. Helsinn Holding Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
    Table 21. Helsinn Holding Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 22. Mundipharma Corporate Information, Head Office, and Major Competitors
    Table 23. Mundipharma Major Business
    Table 24. Mundipharma Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
    Table 25. Mundipharma Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 26. Qilu Pharma Corporate Information, Head Office, and Major Competitors
    Table 27. Qilu Pharma Major Business
    Table 28. Qilu Pharma Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
    Table 29. Qilu Pharma Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 30. Teva Corporate Information, Head Office, and Major Competitors
    Table 31. Teva Major Business
    Table 32. Teva Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
    Table 33. Teva Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 34. Novartis Corporate Information, Head Office, and Major Competitors
    Table 35. Novartis Major Business
    Table 36. Novartis Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
    Table 37. Novartis Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 38. Heron Therapeutics Corporate Information, Head Office, and Major Competitors
    Table 39. Heron Therapeutics Major Business
    Table 40. Heron Therapeutics Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
    Table 41. Heron Therapeutics Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 42. Roche Corporate Information, Head Office, and Major Competitors
    Table 43. Roche Major Business
    Table 44. Roche Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
    Table 45. Roche Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 46. Mylan Corporate Information, Head Office, and Major Competitors
    Table 47. Mylan Major Business
    Table 48. Mylan Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
    Table 49. Mylan Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 50. Tesaro Corporate Information, Head Office, and Major Competitors
    Table 51. Tesaro Major Business
    Table 52. Tesaro Chemotherapy-Induced Nausea and Vomiting (CINV) Product and Solutions
    Table 53. Tesaro Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 54. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
    Table 55. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Share by Players (2019, 2020, 2021, and 2022)
    Table 56. Breakdown of Chemotherapy-Induced Nausea and Vomiting (CINV) by Company Type (Tier 1, Tier 2 and Tier 3)
    Table 57. Chemotherapy-Induced Nausea and Vomiting (CINV) Players Head Office, Products and Services Provided
    Table 58. Chemotherapy-Induced Nausea and Vomiting (CINV) Mergers & Acquisitions in the Past Five Years
    Table 59. Chemotherapy-Induced Nausea and Vomiting (CINV) New Entrants and Expansion Plans
    Table 60. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million) by Type (2017-2022)
    Table 61. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Share by Type (2017-2022)
    Table 62. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Forecast by Type (2023-2028)
    Table 63. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2022)
    Table 64. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Forecast by Application (2023-2028)
    Table 65. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2017-2022) & (USD Million)
    Table 66. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2023-2028) & (USD Million)
    Table 67. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2022) & (USD Million)
    Table 68. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2023-2028) & (USD Million)
    Table 69. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2017-2022) & (USD Million)
    Table 70. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2023-2028) & (USD Million)
    Table 71. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2017-2022) & (USD Million)
    Table 72. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2023-2028) & (USD Million)
    Table 73. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2022) & (USD Million)
    Table 74. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2023-2028) & (USD Million)
    Table 75. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2017-2022) & (USD Million)
    Table 76. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2023-2028) & (USD Million)
    Table 77. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2017-2022) & (USD Million)
    Table 78. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2023-2028) & (USD Million)
    Table 79. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2022) & (USD Million)
    Table 80. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2023-2028) & (USD Million)
    Table 81. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Region (2017-2022) & (USD Million)
    Table 82. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Region (2023-2028) & (USD Million)
    Table 83. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2017-2022) & (USD Million)
    Table 84. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2023-2028) & (USD Million)
    Table 85. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2022) & (USD Million)
    Table 86. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2023-2028) & (USD Million)
    Table 87. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2017-2022) & (USD Million)
    Table 88. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2023-2028) & (USD Million)
    Table 89. Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2017-2022) & (USD Million)
    Table 90. Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Type (2023-2028) & (USD Million)
    Table 91. Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2017-2022) & (USD Million)
    Table 92. Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Application (2023-2028) & (USD Million)
    Table 93. Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2017-2022) & (USD Million)
    Table 94. Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Country (2023-2028) & (USD Million)
List of Figures
    Figure 1. Chemotherapy-Induced Nausea and Vomiting (CINV) Picture
    Figure 2. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Type in 2021
    Figure 3. CINV
    Figure 4. PONV
    Figure 5. Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Application in 2021
    Figure 6. Hospitals Picture
    Figure 7. Ambulatory Surgical Centers Picture
    Figure 8. Diagnostic Centers Picture
    Figure 9. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size, (USD Million): 2017 VS 2021 VS 2028
    Figure 10. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Forecast (2017-2028) & (USD Million)
    Figure 11. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Region (2017-2028)
    Figure 12. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Region in 2021
    Figure 13. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 14. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 15. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 16. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 17. Middle East and Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 18. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Drivers
    Figure 19. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Restraints
    Figure 20. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Trends
    Figure 21. Merck Recent Developments and Future Plans
    Figure 22. Eisai Recent Developments and Future Plans
    Figure 23. ProStrakan Recent Developments and Future Plans
    Figure 24. Helsinn Holding Recent Developments and Future Plans
    Figure 25. Mundipharma Recent Developments and Future Plans
    Figure 26. Qilu Pharma Recent Developments and Future Plans
    Figure 27. Teva Recent Developments and Future Plans
    Figure 28. Novartis Recent Developments and Future Plans
    Figure 29. Heron Therapeutics Recent Developments and Future Plans
    Figure 30. Roche Recent Developments and Future Plans
    Figure 31. Mylan Recent Developments and Future Plans
    Figure 32. Tesaro Recent Developments and Future Plans
    Figure 33. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Share by Players in 2021
    Figure 34. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
    Figure 35. Global Top 3 Players Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share in 2021
    Figure 36. Global Top 10 Players Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share in 2021
    Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
    Figure 38. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Share by Type in 2021
    Figure 39. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share Forecast by Type (2023-2028)
    Figure 40. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Share by Application in 2021
    Figure 41. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share Forecast by Application (2023-2028)
    Figure 42. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Sales Market Share by Type (2017-2028)
    Figure 43. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Sales Market Share by Application (2017-2028)
    Figure 44. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Country (2017-2028)
    Figure 45. United States Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 46. Canada Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 47. Mexico Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 48. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Sales Market Share by Type (2017-2028)
    Figure 49. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Sales Market Share by Application (2017-2028)
    Figure 50. Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Country (2017-2028)
    Figure 51. Germany Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 52. France Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 53. United Kingdom Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 54. Russia Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 55. Italy Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 56. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Sales Market Share by Type (2017-2028)
    Figure 57. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Sales Market Share by Application (2017-2028)
    Figure 58. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Region (2017-2028)
    Figure 59. China Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 60. Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 61. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 62. India Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 63. Southeast Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 64. Australia Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 65. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Sales Market Share by Type (2017-2028)
    Figure 66. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Sales Market Share by Application (2017-2028)
    Figure 67. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Country (2017-2028)
    Figure 68. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 69. Argentina Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 70. Middle East and Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Sales Market Share by Type (2017-2028)
    Figure 71. Middle East and Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Sales Market Share by Application (2017-2028)
    Figure 72. Middle East and Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Country (2017-2028)
    Figure 73. Turkey Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 74. Saudi Arabia Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 75. UAE Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 76. Methodology
    Figure 77. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Merck
Eisai
ProStrakan
Helsinn Holding
Mundipharma
Qilu Pharma
Teva
Novartis
Heron Therapeutics
Roche
Mylan
Tesaro

Related Reports

Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2021 by Company, Regions, Type and Application, Forecast to 2026

Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2021 by Company, Regions, Type and Application, Forecast to 2026

date 25 Feb 2021

date Medical Care

The Chemotherapy-Induced Nausea and Vomiting (CINV) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Product Tags

chemotherapy induced nausea vomiting cinv

chemotherapy induced nausea vomiting cinv drugs

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>